Additional file 1: Table S1. of A novel compound heterozygous variant of the SLC12A3 gene in Gitelman syndrome pedigree

Clinical and biochemical characteristics of all five family members. Clinical and biochemical characteristics of all five family members are listed in Table S1. (DOCX 14 kb

Additional file 2: Table S2. of A novel compound heterozygous variant of the SLC12A3 gene in Gitelman syndrome pedigree

Primer sequences of the SLC12A3 gene and annealing temperature of each pair. Thirty-three primer pairs designed to amplify the coding sequence of the SLC12A3 gene, and annealing temperature of each pair, are provided in Table S2. (DOCX 14 kb

L'Écho : grand quotidien d'information du Centre Ouest

17 juillet 19241924/07/17 (A53).Appartient à l’ensemble documentaire : PoitouCh

Inverse Relationship between Serum Lipoxin A4 Level and the Risk of Metabolic Syndrome in a Middle-Aged Chinese Population

<div><p>Metabolic syndrome (MetS) has been identified to be associated with a state of chronic, low-grade inflammation in adipose tissue. Lipoxins are endogenously generated from arachidonic acid, and exhibit anti-inflammatory actions. Currently, there is no available cohort study identifying the association between serum lipoxins level and MetS. Here we investigate the relationship between serum lipoxin A4 (LXA4) level and the risk of incident MetS in a middle-aged Chinese population. A total 624 participants aged 40–65 years were enrolled at baseline, with 417 (including 333 MetS absence) of them were followed up at 2.5 years. Abdominal visceral fat area (VFA) and abdominal subcutaneous fat area (SFA) were determined using MRI. Serum lipoxin A4 levels were measured by ELISA. At baseline, serum LXA4 levels were significantly correlated with a cluster of traditional MetS risk factors related to obesity (P≤0.05). A higher incidence of new Mets was found in the participants of the lowest tertile of LXA4 levels as compared with that in participants of the highest tertile (P = 0.025). Low serum LXA4 levels [OR 2.607(1.151–5.909), P = 0.022] and high VFA [OR 2.571(1.176–5.620), P = 0.018] were associated with an increased incident Mets, respectively, which remained statistically significant after adjustment for age, gender, current smoking, and alcohol drinking status. Logistic regression analysis suggested a combination of low serum LXA4 levels and high WC/VFA might optimize the prediction of incident Mets in middle-aged Chinese population [OR 4.897/4.967, P = 0.009/0.003]. Decrease in serum LXA4 level and increase in VFA are independent predictors of incident Mets in a population-based cohort, and a combination of them enhances the prognostic value of incident Mets. Taken together, our data suggest that serum LXA4 levels might be useful for early detection and prevention of Mets.</p></div

Correlations Between Serum LXA4 and Metabolic Parameters at Baseline (n = 624).

<p>Abbreviations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142848#pone.0142848.t001" target="_blank">Table 1</a>.</p><p>Correlations Between Serum LXA4 and Metabolic Parameters at Baseline (n = 624).</p

Baseline Characteristics of Participants According to the Presence or Absence of Mets.

<p>Values are presented as mean ± SD for normally distributed continuous variables, median (interquartile range) for skewed variables, and number (%) for categorical variables. P for trend indicates the significance in the difference between participants with and without metabolic syndrome. MetS: metabolic syndrome; LXA4: lipoxin A4; BMI: body mass index; WC: waist circumference; WHR: waist–hip ratio; Fat%: body fat percentage; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; 2h PG: 2-hour postprandial glucose; FINS: fasting insulin; 2h INS: 2-hour insulin; HOMA-IR: homeostatic model assessment of insulin resistance; HbA1c: glycosylated hemoglobin A1c; TC: total cholesterol; LDL-c: low density lipoprotein cholesterol; HDL-c: high density lipoprotein cholesterol; TG: triglyceride; CRP: C-reactive protein; SFA: subcutaneous fat tissue area; VFA: visceral fat tissue area.</p><p>Baseline Characteristics of Participants According to the Presence or Absence of Mets.</p

Association of Baseline LXA4 Concentrations with Metabolic Parameters at 2.5-year Follow-up.

<p>Abbreviations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142848#pone.0142848.t001" target="_blank">Table 1</a>.</p><p>Association of Baseline LXA4 Concentrations with Metabolic Parameters at 2.5-year Follow-up.</p

Risk of MetS at 2.5-year Follow-up Relative to Baseline LXA4 Concentrations, WC and VFA.

<p>Adjusted for age, sex, current smoking, alcohol drinking.</p><p>Abbreviations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142848#pone.0142848.t001" target="_blank">Table 1</a>.</p><p>Risk of MetS at 2.5-year Follow-up Relative to Baseline LXA4 Concentrations, WC and VFA.</p

Effects of T0901317 on insulin function.

<p>A–F, Body weight (A, <i>n</i> = 14–16 mice per group), glucose levels and glucose level area under the curve (AUC) during an intraperitoneal glucose test (IPGTT, 1.5 g glucose per kg body weight) (B), insulin levels and insulin level area under the curve (AUC) during IPGTT (C, <i>n</i> = 7–8 mice per group), glucose levels and glucose level area under the curve (AUC) during an insulin tolerance test (ITT, 0.5 IU insulin per kg body weight, <i>n</i> = 7–8 mice per group) (D), free fatty acid levels (E) and triglyceride levels in serum after an overnight fast (<i>n</i> = 7–8 mice per group). All values are presented as mean ± SEM, *<i>P</i><0.05 and **<i>P</i><0.01 vs. control mice treated with DMSO.</p

Effects of T0901317 adiponectin activity in liver.

<p>A–B, quantitative real-time RT-PCR analyses of adiponectin receptors 1 (AdipoR1) and 2 (AdipoR2) mRNAs in liver (A); Western blotting analyses of phosphorylation of AMPK, phosphorylation of ACC, IRS-1 and PPARα protein levels using β-actin as a loading control in liver (B). All values are presented as means ± SEM, <i>n</i> = 4–6 mice per group. *<i>P</i><0.05, **<i>P</i><0.01 vs. control mice treated with DMSO.</p